This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaufman, E. S. Search for Related Content PubMed PubMed Citation Articles by Kaufman, E. S.

Risk of proarrhythmic events in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study

A multivariate analysis

Elizabeth S. Kaufman, MD, FACC^*,*, Paul A. Zimmermann, MD, FACC, Ted Wang, MD, FACC, George W. Dennish, III, MD, FACC, Patrick D. Barrell, BS^||, Mary L. Chandler, MD, FACOG^||, H. Leon Greene, MD, FACC^|| AFFIRM Investigators

^* MetroHealth Campus of Case Western Reserve University, Cleveland, Ohio, USA
South Carolina Heart Center, Columbia, South Carolina, USA
Advocate Illinois Masonic Medical Center, Chicago, Illinois, USA
Scripps Memorial Hospital, La Jolla, California, USA
^|| Axio Research Corporation, Seattle, Washington, USA

View larger version (15K): [in a new window]   Figure 1 Time to significant ventricular arrhythmias (defined as resuscitated cardiac arrest, torsades de pointes ventricular tachycardia, sustained ventricular tachycardia, or arrhythmic death) in the antiarrhythmic drug arm of the AFFIRM study exposed to quinidine, disopyramide, procainamide, sotalol, ibutilide, or dofetilide at any time.